The antiphospholipid syndrome: ten years on

Minocycline-induced arthritis.

Clinical and experimental rheumatology·1998

Therapeutic advances in systemic lupus erythematosus.

Current opinion in rheumatology·1998

Arterial disease in lupus and secondary antiphospholipid syndrome: association with anti-beta2-glycoprotein I antibodies but not with antibodies against oxidized low-density lipoprotein.

British journal of rheumatology·1998

Lack of cross-reaction between antibodies to beta2-glycoprotein-I and oxidized low-density lipoprotein in patients with antiphospholipid syndrome.

British journal of rheumatology·1998

Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes.

Arthritis and rheumatism·1998

Binding of anticardiolipin antibodies to protein C via beta2-glycoprotein I (beta2-GPI): a possible mechanism in the inhibitory effect of antiphospholipid antibodies on the protein C system.

Clinical and experimental immunology·1998

[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.

Lancet (London, England)·2026

Multivessel coronary artery bypass grafting via small thoracotomy versus sternotomy (MIST): an investigator-initiated, international, open-label, randomised controlled trial.

Lancet (London, England)·2026

Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.

Lancet (London, England)·2026

Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.

Lancet (London, England)·2026

Gender and equity within antimicrobial resistance: a scoping review of evidence and policy in Bangladesh and Sri Lanka.

BMC public health·2026

Justifying antisemitism: Political liberalism and perceptions of prejudices.

The American psychologist·2026

Australia's erosion of peer review.

Science (New York, N.Y.)·2026

Public stigma of mental illness in Australia: shifts in attitudes across nationally representative surveys in 2011 and 2024.

Epidemiology and psychiatric sciences·2026

Working Right Ways in Foot Health With and for First Nations Peoples: Research Method Guided and Governed by First Nations Ways of Knowing, Being, and Doing in Cross-Sectional Qualitative Study Design.

Journal of foot and ankle research·2026

[Autism, acetaminophen, and vaccines: when political rhetoric challenges scientific evidence].

Recenti progressi in medicina·2026

Related Experiment Videos

The antiphospholipid syndrome: ten years on

Related Concept Videos

Minocycline-induced arthritis.

Therapeutic advances in systemic lupus erythematosus.

Arterial disease in lupus and secondary antiphospholipid syndrome: association with anti-beta2-glycoprotein I antibodies but not with antibodies against oxidized low-density lipoprotein.

Lack of cross-reaction between antibodies to beta2-glycoprotein-I and oxidized low-density lipoprotein in patients with antiphospholipid syndrome.

Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes.

Binding of anticardiolipin antibodies to protein C via beta2-glycoprotein I (beta2-GPI): a possible mechanism in the inhibitory effect of antiphospholipid antibodies on the protein C system.

[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.

Multivessel coronary artery bypass grafting via small thoracotomy versus sternotomy (MIST): an investigator-initiated, international, open-label, randomised controlled trial.

Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.

Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.

Gender and equity within antimicrobial resistance: a scoping review of evidence and policy in Bangladesh and Sri Lanka.

Justifying antisemitism: Political liberalism and perceptions of prejudices.

Australia's erosion of peer review.

Public stigma of mental illness in Australia: shifts in attitudes across nationally representative surveys in 2011 and 2024.

Working Right Ways in Foot Health With and for First Nations Peoples: Research Method Guided and Governed by First Nations Ways of Knowing, Being, and Doing in Cross-Sectional Qualitative Study Design.

[Autism, acetaminophen, and vaccines: when political rhetoric challenges scientific evidence].

Related Experiment Videos

The antiphospholipid syndrome: ten years on

Related Concept Videos

Related Articles